Submitted Successfully!
Thank you for your contribution! You can also upload a video entry related to this topic through the link below:
Check Note
Ver. Summary Created by Modification Content Size Created at Operation
1 + 1434 word(s) 1434 2021-01-05 10:50:20 |
2 update layout and reference + 470 word(s) 1904 2021-01-20 10:17:11 |
HLA Class I-Mediated Diseases
Upload a video

HLA (Human Leucocyte Antigen) class I molecules are pivotal in the immuno-surveillance by presenting peptides to CD8+ T cells. However, some of these molecules are involved in the pathogenesis of several autoimmune/autoinflammatory diseases, but the exact role is still elusive. Genome-Wide Association Studies (GWAS) have highlighted other important susceptibility factors such as Endoplasmic Reticulum Aminopeptidase ERAP1 and ERAP2 whose role is to refine the peptides presented by the HLA class I molecules to CD8+ T cells, pointing to an alteration in the antigen presentation as possible pathogenetic mechanism .

HLA class I molecules ERAP1 and ERAP2 Immunopeptidome CD8+ T cells autoimmune/autoinflammatory diseases
Subjects: Immunology
View Times: 72
Revisions: 2 times (View History)
Update Time: 20 Jan 2021

1. Introduction

The MHC (Major Histocompatibility Complex) class I and II molecules, known as HLA (Human Leucocyte Antigen) in humans, are essential for promoting specific immunity; in particular, HLA class I molecules elicit CD8+ T cell responses directed against epitopes, usually nine residues in length, derived from endogenously synthesized microbial or cellular proteins [1]. These peptides, upon the N-terminal refinement by the Endoplasmic Reticulum Aminopeptidases (ERAP) 1 and 2, are accommodated into the groove of the HLA class I molecules through the so-called “anchor” residues that are embedded into specific pockets [2]. In particular, residues at position 2 (P2) and at the carboxy-terminal (PΩ) are pivotal for the correct placement of the peptides through connections with the B and F pocket, respectively [3][4]. The binding motif is generally conserved for each HLA allele. However, some circumstances, such as an inflammatory environment or the use of specific drugs concomitantly with particular ERAP1 and ERAP2 haplotypes, could allow the binding cleft to assume conformations that can become permissive for unconventional peptides. In this context, it is of interest the case of drug-hypersensitivity induced by abacavir in HLA-B*57:01 positive subjects or by carbamazepine in HLA-B*15:02 carriers [5]. In particular, the non-covalent interaction of the drug with the F pocket of HLA-B*57:01 dramatically alters the self-epitope repertoire displayed by the HLA molecule creating foreign complexes, which induce robust T cell responses in the HLA-B*57:01 carriers taking abacavir [6][7][8]. Moreover, several viruses (i.e., HIV, CMV, EBV) could contribute to the alteration of the peptide repertoire establishing their strategies to escape immune surveillance [9].

Ankylosing Spondylitis (AS), Psoriasis (Ps), Birdshot Chorioretinopathy (BSCR) and Behҫet’s disease (BD) are referred as “MHC-I-opathies” as they share an association with HLA-class I genes, in particular HLA-B*27, HLA-C*06:02, HLA-A*29:02 and HLA-B*51, respectively [10]. Such diseases also share ERAP1 and, in some cases, ERAP2 as susceptibility factors and display as overlapping common targets, tissues undergoing either mechanical (enthesis and bone) or environmental stress such as skin, oral mucosa, gut and eye. In spite of different manifestations, a common basis of these diseases at the crossroads between the innate and adaptive immune system, which culminates in the typical chronic inflammation, has been suggested [10].

Over time, several case-control association analyses and Genome-Wide Association Studies (GWAS) have robustly shown associations of Single Nucleotide Polymorphisms (SNPs) in ERAP1 and/or ERAP2 genes or even of entire haplotypes with the above-mentioned diseases [11][12][13][14][15][16][17][18]. Functional effects of this ERAP1 and 2 variance has also been investigated but little is known about the molecular mechanisms in the critical cells. Moreover, few genetic studies have been focused on ERAP gene promoters and on the mechanisms regulating gene expression [19]. In the case of ERAP1, ten haplotypes (Hap1 to Hap10), derived from a combination of multiple non-synonymous SNPs, account for over 99% of the natural ERAP1 variants; however, the association of these haplotypes with each disease is quite different [20]. The striking association with HLA class I molecules and the involvement of ERAPs would point out a central role for CD8+ T cells or even Natural Killer (NK) cells in tissue-specific damage. Accordingly, an altered antigen presentation could be one of the possible mechanisms behind the autoimmune injury caused by some haplotypes of ERAP1 and ERAP2, which are pivotal in the processing of HLA class I epitopes. In fact, an altered pool of peptides accounting for the ‘mis-immunopeptidome’ that ranges from suboptimal to pathogenetic/harmful peptides could be able to induce non-canonical or autoreactive CD8+ T responses, activation of NK cells and/or garbling the classical functions of the HLA class I molecules [21].

2. HLA-B*27 and Spondyloarthropathies: Beyond the ‘Classical’ Peptidome

The HLA-B*27 is one of the most investigated HLA class I molecule that came to the attention during the early 1970s for its association with AS and other related inflammatory disorders collectively known as seronegative Spondyloarthropathies (SpA), which comprise Psoriatic Arthritis (PsA), Reactive Arthritis (ReA), Anterior Uveitis-associated Arthritis and the Arthritis linked to Inflammatory Bowel Disease (IBD). However, an univocal explanation for this remarkable linking is still lacking [21][22]. Several scenarios take into account not only the canonical function of HLA-B*27 as peptide presenting molecule to cytotoxic CD8+ T lymphocytes (CTLs) or ligand for NK receptors, but also some “aberrant” features such as misfolding and homodimerization [23]. On the other hand, the HLA-B*27 has been described as protective factor against several viral infections (HIV, HCV, EBV and influenza virus), probably due to a better performance of the virus specific HLA-B*27-restricted CD8+ T cells [17][24]. Ideally, the common ground of these two aspects could be the peptidome. In fact, the quality and the quantity of peptides available for the binding to the HLA-B*27 molecules could affect their stability and function. Investigating the immunopeptidome is therefore useful to design more specific therapies.

HLA-B*27 is highly polymorphic with more than 200 subtypes [25] identified so far, but not all associated with AS [26]. Of note, most of the variance is located in the binding groove cleft, substantiating the relevance of the peptide repertoire. Despite the attempts to identify a specific peptidome displayed by the AS-associated molecules (HLA-B*27:05, -B*27:02, -B*27:04 and -B*27:07) versus the non-AS-associated ones (HLA-B*27:06 and -B*27:09) no definitive answer has emerged as yet [27][28]. However, it is still worth pursuing this goal focusing on a pair of alleles that show a different association with AS such as HLA-B*27:05 and HLA-B*27:09, differing for a single amino acid (Asp116His), or B*27:04 and B*27:06 differing for two amino acids [29][30].

The HLA-B*27 peptidome consists mainly of 9-mers and 10-mers [31] with Arg at P2 and basic, aliphatic or aromatic residues at C-terminus [18]. Although a hallmark of the B27 peptidome is an Arg as main anchor at P2, recent studies have introduced Gln and Lys as alternative P2 residues, albeit much lower represented compared to Arg [32][33]. In this context, Lorente and colleagues have shown that these two amino acids are enriched at P2 in the HLA-B*27:05 ligandome when ERAP2 is absent [34]. The authors also found an increase of basic residues at N-terminal with a concurrent reduction of hydrophobic amino acids at P3, P7 and P9 [34].

Before migrating to the cell surface, the HLA-B*27 molecules load the peptide cargo in the Endoplasmic Reticulum (ER). Interestingly, the tendency of HLA-B*27 molecules to fold slowly and to be retained in the ER in a peptide-receptive state could give to suboptimal peptides the chance to accommodate into the groove at the expense of classical B27 epitopes [35]. The peptide loading efficiency of HLA-B*27 molecules is therefore the result of their receptive state and is strongly influenced by qualitative and quantitative fluctuation of ERAP1 and 2. Notably, there is an epistatic gene-gene interaction between HLA-B*27 and ERAP1, since the association of ERAP1 with AS occurs only in HLA-B*27 positive patients, whereas the association of ERAP2 is independent of HLA-B*27, suggesting for ERAP2 a role distinct from antigen processing [11][12][36][37]. Now we know that the combination of highly active ERAP1 variants (Hap1 to Hap3) and the presence of ERAP2 could promote AS, whereas the opposite seems to be protective [20]. It is not clear whether this could be due to a “disruption” of canonical B27 peptides with consequent generation of new potentially pathogenetic epitopes [38]. In particular, the co-presence of ERAP2 with highly active ERAP1 variants (Hap1 and Hap2) favored an increase of 9-mers with a reduction of basic P1 residues [39]. Moreover, studies from human cells and transgenic rats showed that the depletion of ERAP1 induced the switch of the B27 peptidome towards longer peptides, C-terminally extended, and an alteration on the frequency of P1 residues [40][41]. Notably, longer peptides have been already described as intermediates or accidentally bound peptides with a lower frequency of the Arg in P2 [42]. In addition, the silencing or the inhibition of ERAP1 seemed to promote the reduction of FHC (Free Heavy Chain) homodimers on the surface of C1R and HeLa stably expressing HLA-B*27 as well as on monocytes from AS patients [43], suggesting that lowering the activity of ERAP1 as in the case of protective variants could preserve the stability of HLA-B*27 molecules providing an optimal ligandome.

The nature of the peptidome efficiently bound and presented by HLA-B*27 is highly influenced by the stability of the molecule itself; several studies have described a higher flexibility of HLA-B*27:05, compared to B*27:09, suggesting an intrinsic propensity of this subtype to adopt unconventional conformations, especially in the proximity of the binding groove [44][45][46]. Moreover, a recent work by Loll’s research group has suggested that HLA-B*27:05, but not B*27:09, undergoes metal ion-induced conformational alterations that, in turn, could influence the capability of the AS-associated allele to bind suboptimal peptides [47].

Our group has recently described a polymorphism, SNP rs75862629, located in the intergenic region between ERAP1 and ERAP2 that can affect the expression of both genes and, consequently, of HLA-B*27 molecules [19][48]. In particular, we showed that in the Sardinian population, the G variant, implicating high ERAP1 and low ERAP2 levels, induces a reduction in the surface expression of HLA-B*27:09, but not of HLA-B*27:05 [48]. In this regard, it is known that increased levels of HLA-B*27 expression also promote AS susceptibility [49]. In principle, the “disruption” of the conventional B27 peptidome due to the over-trimming by ERAP1 could cause an increase in suboptimal peptides that are not suitable for the B*27:09 binding but good enough for maintaining B*27:05 stability on the cell surface. As we recently reported, the higher flexibility of the HLA-B*27:05 binding groove and its low dependence on a classical B27 peptidome allow HLA-B*27:05 to present a HLA-B*07 restricted viral peptide (pEBNA3A-RPPIFIRRL) lacking the B27 consensus motif (Arg2) and nevertheless promoting the activation of specific CD8+ T cells. This response is not evoked by the HLA-B*27:09, remarking the lower stringency of the peptide repertoire bound by HLA-B*27:05 [50][51]. At present, we are investigating a possible correlation between this particular CD8+ T response in the context of HLA-B*27:05 and a specific haplotype of ERAP1 and ERAP2 (unpublished data). In this context, Rowntree et al. reported that several peptides derived from viruses causing chronic infections (EBV, CMV and HIV-1), usually displayed by the HLA-A*02, HLA-B*07 or HLA-B*57, could induce alloreactive CD8+ T cell responses towards HLA-B*27 [52]. Consistently, we also showed that the HLA-B*27 molecules can present viral epitopes introduced by chimeric proteins driven by TAT of HIV through a proteasome- and TAP-independent pathway, pointing out again the high flexibility of the HLA-B*27 molecules [53].

Another important aspect is the subclinical gut inflammation occurring in up to 70% of patients with AS as a possible consequence of microbial dysbiosis [54]. The alteration of the gut microbiota could be, at least in part, related to the activation of autoreactive CD8+ T cells towards microbial peptides displayed by HLA-B*27 [55]. Accordingly, the permissive binding of HLA-B*27:05 could enlarge the spectrum of the candidate epitopes.

The complexity of B27 peptidome, especially of B*27:05, is far from an unambiguous definition; matching mass spectrometry analyses with functional studies, could shed light on its double role as a protective factor in viral infections and as a predisposing molecule in the autoimmune diseases.


  1. Van Hateren, A.; James, E.; Bailey, A.; Phillips, A.; Dalchau, N.; Elliott, T. The cell biology of major histocompatibility complex class I assembly: Towards a molecular understanding. Tissue Antigens 2010, 76, 259–275, doi:10.1111/j.1399-0039.2010.01550.x.
  2. Evnouchidou, I.; van Endert, P. Peptide trimming by endoplasmic reticulum aminopeptidases: Role of MHC class I binding and ERAP dimerization. Immunol. 2019, 80, 290–295, doi:10.1016/j.humimm.2019.01.003.
  3. Khan, A.R.; Baker, B.M.; Ghosh, P.; Biddison, W.E.; Wiley, D.C. The structure and stability of an HLA-A*0201/octameric tax peptide complex with an empty conserved peptide-N-terminal binding site. Immunol. 2000, 164, 6398–6405, doi:10.4049/jimmunol.164.12.6398.
  4. Madden, D.R.; Gorga, J.C.; Strominger, J.L.; Wiley, D.C. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 1991, 353, 321–325, doi:10.1038/353321a0.
  5. Ostrov, D.A.; Grant, B.J.; Pompeu, Y.A.; Sidney, J.; Harndahl, M.; Southwood, S.; Oseroff, C.; Lu, S.; Jakoncic, J.; de Oliveira, C.A.F.; et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Natl. Acad. Sci. USA 2012, 109, 9959–9964, doi:10.1073/pnas.1207934109.
  6. Norcross, M.A.; Luo, S.; Lu, L.; Boyne, M.T.; Gomarteli, M.; Rennels, A.D.; Woodcock, J.; Margulies, D.H.; McMurtrey, C.; Vernon, S.; et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: An autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012, 26, F21–F29, doi:10.1097/QAD.0b013e328355fe8f.
  7. Fiorillo, M.T.; Paladini, F.; Tedeschi, V.; Sorrentino, R. HLA Class I or Class II and Disease Association: Catch the Difference If You Can. Immunol. 2017, 8, 1475, doi:10.3389/fimmu.2017.01475.
  8. Abels, W.C.; Celik, A.A.; Simper, G.S.; Blasczyk, R.; Bade-Döding, C. Peptide Presentation Is the Key to Immunotherapeutical Success. In Polypeptide—New Insight into Drug Discovery and Development; Tambunan, U.S.F., Ed.; IntechOpen: London, UK, 2018; pp. 7–25, doi:5772/intechopen.76871.
  9. McGonagle, D.; Aydin, S.Z.; Gül, A.; Mahr, A.; Direskeneli, H. ‘MHC-I-opathy’-unified concept for spondyloarthritis and Behçet disease. Rev. Rheumatol. 2015, 11, 731–740, doi:10.1038/nrrheum.2015.147.
  10. Evans, D.M.; Spencer, C.C.; Pointon, J.J.; Su, Z.; Harvey, D.; Kochan, G.; Oppermann, U.; Dilthey, A.; Pirinen, M.; Stone, M.A.; et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Genet. 2011, 43, 761–767, doi:10.1038/ng.873.
  11. Robinson, P.C.; Costello, M.E.; Leo, P.; Bradbury, L.A.; Hollis, K.; Cortes, A.; Lee, S.; Joo, K.B.; Shim, S.C.; Weisman, M.; et al. ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients. Rheum. Dis. 2015, 74, 1627–1629, doi:10.1136/annrheumdis-2015-207416.
  12. Kirino, Y.; Bertsias, G.; Ishigatsubo, Y.; Mizuki, N.; Tugal-Tutkun, I.; Seyahi, E.; Ozyazgan, Y.; Sacli, F.S.; Erer, B.; Inoko, H.; et al. Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B*51 and ERAP1. Genet. 2013, 45, 202–207, doi:10.1038/ng.2520.
  13. Kuiper, J.J.; Van Setten, J.; Ripke, S.; Van 'T Slot, R.; Mulder, F.; Missotten, T.; Baarsma, G.S.; Francioli, L.C.; Pulit, S.L.; De Kovel, C.G.; et al. A genome-wide association study identifies a functional ERAP2 haplotype associated with birdshot chorioretinopathy. Mol. Genet. 2014, 23, 6081–6087, doi:10.1093/hmg/ddu307.
  14. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange, A.; Capon, F.; Spencer, C.C.; Knight, J.; Weale, M.E.; Allen, M.H.; Barton, A.; Band, G.; Bellenguez, C.; et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Genet. 2010, 42, 985–990, doi:10.1038/ng.694.
  15. Costantino, F.; Breban, M.; Garchon, H.J. Genetics and Functional Genomics of Spondyloarthritis. Immunol. 2018, 9, 2933, doi:10.3389/fimmu.2018.02933.
  16. Vitulano, C.; Tedeschi, V.; Paladini, F.; Sorrentino, R.; Fiorillo, M.T. The interplay between HLA-B27 and ERAP1/ERAP2 aminopeptidases: From anti-viral protection to spondyloarthritis. Exp. Immunol. 2017, 190, 281–290, doi:10.1111/cei.13020.
  17. López de Castro, J.A. How ERAP1 and ERAP2 Shape the Peptidomes of Disease-Associated MHC-I Proteins. Immunol. 2018, 9, 2463, doi:10.3389/fimmu.2018.02463.
  18. Paladini, F.; Fiorillo, M.T.; Vitulano, C.; Tedeschi, V.; Piga, M.; Cauli, A.; Mathieu, A.; Sorrentino, R. An allelic variant in the intergenic region between ERAP1 and ERAP2 correlates with an inverse expression of the two genes. Rep. 2018, 8, 10398, doi:10.1038/s41598-018-28799.
  19. Ombrello, M.J.; Kastner, D.L.; Remmers, E.F. Endoplasmic reticulum-associated amino-peptidase 1 and rheumatic disease: Genetics. Opin. Rheumatol. 2015, 27, 349–356, doi:10.1097/BOR.0000000000000189.
  20. Tedeschi, V.; Paldino, G.; Paladini, F.; Mattorre, B.; Tuosto, L.; Sorrentino, R.; Fiorillo, M.T. The Impact of the 'Mis-Peptidome' on HLA Class I-Mediated Diseases: Contribution of ERAP1 and ERAP2 and Effects on the Immune Response. Int J Mol Sci. 2020, 21, 9608. doi:10.3390/ijms21249608.
  21. Schlosstein, L.; Terasaki, P.I.; Bluestone, R.; Pearson, C.M. High association of an HL-A antigen, W27, with ankylosing spondylitis. N. Engl. J. Med. 1973, 288, 704–706, doi:10.1056/NEJM197304052881403.
  22. Colbert, R.A.; Navid, F.; Gill, T. The role of HLA-B*27 in spondyloarthritis. Best Pract. Res. Clin. Rheumatol. 2017, 31, 797–815, doi:10.1016/j.berh.2018.07.012.
  23. Neumann-Haefelin, C. HLA-B7-mediated protection in HIV and hepatitis C virus infection and pathogenesis in spondyloarthritis: Two sides of the same coin? Curr. Opin. Rheumatol. 2013, 25, 426–433, doi:10.1097/BOR.0b013e328362018f.
  24. IPD-IMGT/HLA. Available online: (accessed on 15 December 2020).
  25. Díaz-Peña, R.; López-Vázquez, A.; López-Larrea, C. Old and new HLA associations with ankylosing spondylitis. Tissue Antigens 2012, 80, 205–213, doi:10.1111/j.1399-0039.2012.01944.x.
  26. Ben Dror, L.; Barnea, E.; Beer, I.; Mann, M.; Admon, A. The HLA-B*27:05 peptidome. Arthritis Rheum. 2010, 62, 420–429, doi:10.1002/art.27257.
  27. Schittenhelm, R.B.; Sian, T.C.; Wilmann, P.G.; Dudek, N.L.; Purcell, A.W. Revisiting the arthritogenic peptide theory: Quantitative not qualitative changes in the peptide repertoire of HLA-B27 allotypes. Arthritis Rheumatol. 2015, 67, 702–713, doi:10.1002/art.38963.
  28. D’Amato, M.; Fiorillo, M.T.; Carcassi, C.; Mathieu, A.; Zuccarelli, A.; Bitti, P.P.; Tosi, R.; Sorrentino, R. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur. J. Immunol. 1995, 25, 3199–3201, doi:10.1002/eji.1830251133.
  29. Lin, J.; Lu, H.; Feng, C. Ankylosing spondylitis and heterogenity of HLA-B27 in Chinese. Chin. J. Surg. 1996, 34, 333–335.
  30. García-Medel, N.; Sanz-Bravo, A.; Alvarez-Navarro, C.; Gómez-Molina, P.; Barnea, E.; Marcilla, M.; Admon, A.; de Castro, J.A. Peptide handling by HLA-B27 subtypes influences their biological behavior, association with ankylosing spondylitis and susceptibility to endoplasmic reticulum aminopeptidase 1 (ERAP1). Mol. Cell. Proteom. 2014, 13, 3367–3380, doi:10.1074/mcp.M114.039214.
  31. Infantes, S.; Lorente, E.; Barnea, E.; Beer, I., Barriga, A.; Lasala, F.; Jiménez, M.; Admon, A.; López, D. Natural HLA-B*27:05 protein ligands with glutamine as anchor motif: Implications for HLA-B27 association with spondyloarthropathy. J. Biol. Chem. 2013, 288, 10882–10889, doi:10.1074/jbc.M113.455352.
  32. Yair-Sabag, S.; Tedeschi, V.; Vitulano, C.; Barnea, E.; Glaser, F.; Melamed Kadosh, D.; Taurog, J.D.; Fiorillo, M.T.; Sorrentino, R.; Admon, A. The Peptide Repertoire of HLA-B27 may include Ligands with Lysine at P2 Anchor Position. Proteomics 2018, 18, e1700249, doi:10.1002/pmic.201700249.
  33. Lorente, E.; Fontela, M.G.; Barnea, E.; Martín-Galiano, A.J.; Mir, C.; Galocha, B.; Admon, A.; Lauzurica, P.; López, D. Modulation of Natural HLA-B*27:05 Ligandome by Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 2 (ERAP2). Mol. Cell. Proteom. 2020, 19, 994–1004, doi:10.1074/mcp.RA120.002014.
  34. Colbert, R.A.; DeLay, M.L.; Layh-Schmitt, G.; Sowders, D.P. HLA-B27 misfolding and spondyloarthropathies. Prion 2009, 3, 15–26, doi:10.4161/pri.3.1.8072.
  35. Paladini, F.; Fiorillo, M.T.; Tedeschi, V.; Cauli, A.; Mathieu, A.; Sorrentino, R. Ankylosing Spondylitis: A Trade Off of HLA-B27, ERAP, and Pathogen Interconnections? Focus on Sardinia. Front. Immunol. 2019, 10, 35, doi:10.3389/fimmu.2019.00035.
  36. Paladini, F.; Fiorillo., M.T.; Tedeschi, V.; Mattorre, B.; Sorrentino, R. The Multifaceted Nature of Aminopeptidases ERAP1, ERAP2, and LNPEP: From Evolution to Disease. Front. Immunol. 2020, 11, 1576, doi:10.3389/fimmu.2020.01576.
  37. Reeves, E.; James, E. The role of polymorphic ERAP1 in autoinflammatory disease. Biosci. Rep. 2018, 38, BSR20171503, doi:10.1042/BSR20171503.
  38. Martín-Esteban, A.; Guasp, P.; Barnea, E.; Admon, A.; López de Castro, J.A. Functional Interaction of the Ankylosing Spondylitis-Associated Endoplasmic Reticulum Aminopeptidase 2 With the HLA-B*27 Peptidome in Human Cells. Arthritis Rheumatol. 2016, 68, 2466–2475, doi:10.1002/art.39734.
  39. Chen, L.; Fischer, R.; Peng, Y.; Reeves, E.; McHugh, K.; Ternette, N.; Hanke, T.; Dong, T.; Elliott, T.; Shastri, N.; et al. Critical role of endoplasmic reticulum aminopeptidase 1 in determining the length and sequence of peptides bound and presented by HLA-B27. Arthritis Rheumatol. 2014, 66, 284–294, doi:10.1002/art.38249.
  40. Barnea, E.; Melamed Kadosh, D.; Haimovich, Y.; Satumtira, N.; Dorris, M.L.; Nguyen, M.T.; Hammer, R.E.; Tran, T.M.; Colbert, R.A.; Taurog, J.D.; et al. The Human Leukocyte Antigen (HLA)-B27 Peptidome in Vivo, in Spondyloarthritis-susceptible HLA-B27 Transgenic Rats and the Effect of Erap1 Deletion. Mol. Cell. Proteom. 2017, 16, 642–662, doi:10.1074/mcp.M116.066241.
  41. Urban, R.G.; Chicz, R.M.; Lane, W.S.; Strominger, J.L.; Rehm, A.; Kenter, M.J.; UytdeHaag, F.G.; Ploegh, H.; Uchanska-Ziegler, B.; Ziegler, A. A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc. Natl. Acad. Sci. USA 1994, 91, 1534–1538, doi:10.1073/pnas.91.4.1534.
  42. Chen, L.; Ridley, A.; Hammitzsch, A.; Al-Mossawi, M.H.; Bunting, H.; Georgiadis, D.; Chan, A.; Kollnberger, S.; Bowness, P. Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis. Ann. Rheum. Dis. 2016, 75, 916–923, doi:10.1136/annrheumdis-2014-206996.
  43. Fabian, H.; Huser, H.; Loll, B.; Ziegler, A.; Naumann, D.; Uchanska-Ziegler, B. HLA-B27 heavy chains distinguished by a micropolymorphism exhibit differential flexibility. Arthritis Rheum. 2010, 62, 978–987, doi:10.1002/art.27316.
  44. Narzi, D.; Becker, C.M.; Fiorillo, M.T.; Uchanska-Ziegler, B.; Ziegler, A.; Böckmann, R.A. Dynamical characterization of two differentially disease associated MHC class I proteins in complex with viral and self-peptides. J. Mol. Biol. 2012, 415, 429–442, doi:10.1016/j.jmb.2011.11.021.
  45. Loll, B.; Rückert, C.; Uchanska-Ziegler, B.; Ziegler, A. Conformational Plasticity of HLA-B27 Molecules Correlates Inversely with Efficiency of Negative T Cell Selection. Front. Immunol. 2020, 11, 179, doi:10.3389/fimmu.2020.00179.
  46. Driller, R.; Ballaschk, M.; Schmieder, P.; Uchanska-Ziegler, B.; Ziegler, A.; Loll, B. Metal-triggered conformational reorientation of a self-peptide bound to a disease-associated HLA-B*27 subtype. J. Biol. Chem. 2019, 294, 13269–13279, doi:10.1074/jbc.RA119.008937.
  47. Paladini, F.; Fiorillo, M.T.; Tedeschi, V.; D'Otolo, V.; Piga, M.; Cauli, A.; Mathieu, A.; Sorrentino, R. The rs75862629 minor allele in the endoplasmic reticulum aminopeptidases intergenic region affects human leucocyte antigen B27 expression and protects from ankylosing spondylitis in Sardinia. Rheumatology 2019, 58, 2315–2324, doi:10.1093/rheumatology/kez212.
  48. Cauli, A.; Dessole, G.; Vacca, A.; Porru, G.; Cappai, L.; Piga, M.; Bitti, P.P.; Fiorillo, M.T.; Sorrentino, R.; Carcassi, C.; et al. Susceptibility to ankylosing spondylitis but not disease outcome is influenced by the level of HLA-B27 expression, which shows moderate variability over time. Scand. J. Rheumatol. 2012, 41, 214–218, doi:10.3109/03009742.2011.623138.
  49. Tedeschi, V.; Vitulano, C.; Cauli, A.; Paladini, F.; Piga, M.; Mathieu, A.; Sorrentino, R.; Fiorillo, M.T. The Ankylosing Spondylitis-associated HLA-B*27:05 presents a B*0702-restricted EBV epitope and sustains the clonal amplification of cytotoxic T cells in patients. Mol. Med. 2016, 22, 215–223, doi:10.2119/molmed.2016.00031.
  50. Tedeschi, V.; Alba, J.; Paladini, F.; Paroli, M.; Cauli, A.; Mathieu, A.; Sorrentino, R.; D'Abramo, M.; Fiorillo, M.T. Unusual Placement of an EBV Epitope into the Groove of the Ankylosing Spondylitis-Associated HLA-B27 Allele Allows CD8+ T Cell Activation. Cells 2019, 8, 572, doi:10.3390/cells8060572.
  51. Rowntree, L.C.; van den Heuvel, H.; Sun, J.; D'Orsogna, L.J.; Nguyen, T.; Claas, F.; Rossjohn, J.; Kotsimbos, T.C.; Purcell, A.W.; Mifsud, N.A. Preferential HLA-B27 Allorecognition Displayed by Multiple Cross-Reactive Antiviral CD8+ T Cell Receptors. Front. Immunol. 2020, 11, 248, doi:10.3389/fimmu.2020.00248.
  52. Magnacca, A.; Persiconi, I.; Nurzia, E.; Caristi, S.; Meloni, F.; Barnaba, V.; Paladini, F.; Raimondo, D.; Fiorillo, M.T.; Sorrentino, R. Characterization of a proteasome and TAP-independent presentation of intracellular epitopes by HLA-B27 molecules. J. Biol. Chem. 2012, 287, 30358–30367, doi:10.1074/jbc.M112.384339.
  53. Costello, M.E.; Ciccia, F.; Willner, D.; Warrington, N.; Robinson, P.C.; Gardiner, B.; Marshall, M.; Kenna, T.J.; Triolo, G.; Brown, M.A. Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis. Arthritis Rheumatol. 2015, 67, 686–691, doi:10.1002/art.38967.
  54. Costello, M.E.; Ciccia, F.; Willner, D.; Warrington, N.; Robinson, P.C.; Gardiner, B.; Marshall, M.; Kenna, T.J.; Triolo, G.; Brown, M.A. Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis. Arthritis Rheumatol. 2015, 67, 686–691, doi:10.1002/art.38967.
  55. 55. Yin, J.; Sternes, P.R.; Wang, M.; Song, J.; Morrison, M.; Li, T.; Zhou, L.; Wu, X.; He, F.; Zhu, J.; et al. Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition. Ann. Rheum. Dis. 2020, 79, 132–140, doi:10.1136/annrheumdis-2019-215763.
Subjects: Immunology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : ,
View Times: 72
Revisions: 2 times (View History)
Update Time: 20 Jan 2021
Table of Contents


    Are you sure to Delete?

    Video Upload Options

    Do you have a full video?
    If you have any further questions, please contact Encyclopedia Editorial Office.
    Tedeschi, V.; Sorrentino, R. HLA Class I-Mediated Diseases. Encyclopedia. Available online: (accessed on 03 October 2022).
    Tedeschi V, Sorrentino R. HLA Class I-Mediated Diseases. Encyclopedia. Available at: Accessed October 03, 2022.
    Tedeschi, Valentina, Rosa Sorrentino. "HLA Class I-Mediated Diseases," Encyclopedia, (accessed October 03, 2022).
    Tedeschi, V., & Sorrentino, R. (2021, January 19). HLA Class I-Mediated Diseases. In Encyclopedia.
    Tedeschi, Valentina and Rosa Sorrentino. ''HLA Class I-Mediated Diseases.'' Encyclopedia. Web. 19 January, 2021.